Sand Hill Global Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.84M Buy
6,369
+1,193
+23% +$556K 0.1% 92
2025
Q4
$2.35M Sell
5,176
-1,550
-23% -$668K 0.08% 97
2025
Q3
$2.63M Sell
6,726
-594
-8% -$248K 0.09% 97
2025
Q2
$3.26M Buy
7,320
+395
+6% +$182K 0.12% 91
2025
Q1
$3.36M Buy
+6,925
New +$3.23M 0.14% 84

Other funds holding VRTX

Sand Hill Global Advisors's VRTX Position: Q1 2026 in Review

Sand Hill Global Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 23% in Q1 2026, buying an estimated $556K and bringing the position to 6,369 shares worth $2.84M. The position accounts for 0.1% of the portfolio, ranked #92.

Sand Hill Global Advisors first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.36M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Sand Hill Global Advisors held 6,369 shares of Vertex Pharmaceuticals worth $2.84M as of Q1 2026.
  • Sand Hill Global Advisors bought 1,193 Vertex Pharmaceuticals shares in Q1 2026, an estimated $556K.
  • Vertex Pharmaceuticals made up 0.1% of Sand Hill Global Advisors's portfolio in Q1 2026, its #92 holding.
  • Sand Hill Global Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Sand Hill Global Advisors's Vertex Pharmaceuticals position peaked at $3.36M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Sand Hill Global Advisors's 13F filing for Q1 2026, filed 14 May 2026.